Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Cancer Res. 2021 Nov 5;82(1):155–168. doi: 10.1158/0008-5472.CAN-20-3845

Figure 7: NXTAR derived oligonucleotide NXTAR-N5 suppresses prostate cancer proliferation.

Figure 7:

A, Location of NXTAR-N5 binding region upstream of AR gene shown in a graphical format. B, BLASTN analysis showing regions of significant homology (complementarity to other strand) in the upstream regions of AR and exon 5 of NXTAR. C, The NXTAR-N5 oligonucleotide sequence is shown. *Represents a Phosphorothioate bonds modifications to avoid degradation by exonucleases. D, VCaP and 22Rv1 cells were transfected with NXTAR-N5 oligonucleotide and cell proliferation was measured using trypan blue exclusion method. E, VCaP and 22Rv1 cells were transfected with NXTAR-N5, and RNA was prepared, followed by qRT-PCR for AR and AR-V7 mRNA. F, Biotin conjugated NXTAR-N5 and Globin oligos were incubated with lysate from fixed VCaP cells and qPCR was performed for AR Up1.1 primers (see Fig. 7A). G, VCaP cell lysate was subjected to chromatin pull down using NXTAR-N5 biotin conjugated oligos, followed by immunoblotting for EZH2. Actin was used as loading control. H, NXTAR-N5 and Globin oligos were incubated with purified EZH2. Pull-down were washed, followed by immunoblotting with EZH2 antibodies. I, VCaP cells were transfected with Globin and NXTAR-N5 oligos and subjected to ChIP with H3K27me3 antibody followed by qPCR for site upstream of AR TSS (−0.7kb). Data are represented as mean ± SEM. **p<0.01. *** p<0.001.